Atlas Trials

Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

Clinical trial NCT04829747 · COMPLETED

Trial details

NCT number
NCT04829747
Sponsor
Allergan
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Migraine
Start date
2021-08-02
Primary completion
2022-01-20
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.